Mad Honey Poisoning Treatment Protocol: Stepwise Clinical Management with Pharmacological Rationale

This article documents the clinical management protocol for grayanotoxin (GTX) poisoning from mad honey consumption, as established in the peer-reviewed literature, primarily Ullah et al. (2018), Jansen et al. (2012), and the case series synthesised by Silici and Atayoglu (2015). It is a reference document for emergency medicine clinicians, internal medicine physicians, cardiologists, and medical educators.

This article is distinct from the CMHI Emergency Response guide (consumer-facing) and the Ullah et al. (2018) paper summary. It organises the clinical information as a stepwise protocol with the mechanism explanation for each intervention, the escalation criteria, and the evidence basis for each recommendation.

Contents

1. Diagnosis: No Laboratory Testing Required
2. Severity Stratification
3. The Four-Step Treatment Protocol
4. ECG Monitoring: Findings and Actions
5. Special Populations
6. What Not to Do
7. Discharge Criteria and Observation Period
8. Evidence Base and Limitations
9. What We Don’t Know Yet
10. Summary Protocol Reference
11. Sources

Diagnosis: No Laboratory Testing Required

Mad honey poisoning can be diagnosed on clinical history and physical examination alone, without laboratory confirmation. Ullah et al. (2018) established this explicitly: the combination of bradycardia, hypotension, and dizziness following honey consumption is sufficient to initiate treatment without waiting for toxicological confirmation.

Clinical triad

Bradycardia, hypotension, and dizziness with or without secondary neurological symptoms. Across published series, mean values on arrival ranged from 38 to 56 beats per minute and from 73 to 102 mmHg systolic (Okuyan et al. 2010; Demir et al. 2011). All three components arising together following honey consumption provide a high-confidence differential diagnosis.

Consumption history

Ask directly: what honey was consumed, how much, and when. In endemic regions (Turkey’s Black Sea coast, Nepal’s highland districts), the differential is immediately clear. In non-endemic settings, Europe, North America, and East Asia, mad honey poisoning may not be the first diagnosis considered. In any patient with unexplained bradycardia and hypotension, dietary history, including honey consumption, should be included in the acute assessment.

ECG: the primary monitoring tool

Obtain an ECG immediately. It establishes the severity of conduction impairment, guides treatment escalation, and provides the baseline for monitoring response. ECG findings in order of severity: sinus bradycardia, first-degree AV block (PR greater than 200 ms), second-degree AV block (Wenckebach / Mobitz I), complete (third-degree) AV block, atrial fibrillation, ventricular escape rhythm. The ECG finding drives the escalation decision.

Severity Stratification

• Mild: dizziness and mild hypotension (Ullah et al. 2018), ambulatory, sinus bradycardia on ECG without block. Management: IV access, monitoring, IV saline may be sufficient.
• Moderate: pronounced symptoms, first or second degree AV block on ECG. Management: IV saline plus atropine required.
• Severe: severe bradycardia, very low or unrecordable blood pressure, complete AV block or haemodynamically compromising arrhythmia, syncope or altered consciousness. Management: full escalation protocol.

No validated severity score exists for mad honey poisoning, so these groupings describe presentations rather than fixed cut-offs. A 2013 conference report on 246 patients, summarised by EFSA (2023), counted a heart rate of 40 beats per minute or below as severe bradycardia (61 patients) and a systolic pressure of 60 mmHg or below as severe hypotension (33 patients) (Sumerkan et al. 2013).

The Four-Step Treatment Protocol

 

Step 1: IV Fluid Resuscitation

IV fluid resuscitation addresses hypotension by restoring circulating volume and peripheral vascular filling pressure. GTX produces hypotension through two simultaneous mechanisms: reduced cardiac output from bradycardia, and peripheral vasodilation from impaired sympathetic vasoconstrictor tone. Saline addresses the vascular filling component but not the cardiac rate component, which is why atropine is required alongside rather than instead of it.

Ullah et al. (2018) describe saline infusion, given alone or together with atropine. In one series of 16 patients, a mean of 1,125 mL of saline was used alongside atropine (Yaylaci et al. 2014). In elderly patients with pre-existing cardiac conditions, volume loading should be titrated carefully.

Step 2: Atropine Sulphate, Mechanism, Dosing, and Response

Why atropine works specifically for GTX poisoning

GTX amplifies vagal tone through two compounding mechanisms: sustained VGSC depolarisation in autonomic neurons increases acetylcholine release at cardiac nerve terminals, and direct VGSC disruption in nodal cells impairs intrinsic pacemaker and conduction function. Atropine is a competitive antagonist at M2 muscarinic receptors at the SA and AV nodes. By blocking M2, atropine counteracts the vagal amplification regardless of acetylcholine release levels.

Atropine’s efficacy in most GTX poisoning cases pharmacologically confirms that vagally-mediated bradycardia is the dominant mechanism in typical presentations. The SA node’s pacemaker function is suppressed rather than damaged; it recovers as GTX clears.

Dosing and response

Ullah et al. (2018) document atropine doses of 0.5 to 2 mg IV across the case record. In the largest review of published cases, most patients received 0.5 mg or 1 mg (Silici and Atayoglu 2015). Heart rate normalisation in atropine-responsive cases typically occurs within minutes of IV administration.

When atropine is insufficient

Cases where atropine provides only partial reversal involve elderly patients, those with pre-existing conduction abnormalities, or very high GTX exposure. Why atropine is not always enough is not settled: Jansen et al. (2012) note that whether grayanotoxin also acts directly on heart muscle cells through the sodium channel still has to be determined.

Step 3: Catecholamine Support

Catecholamine support is indicated when haemodynamic compromise continues after adequate fluids and atropine. Ullah et al. (2018) suggest adrenaline (epinephrine) or dopamine infusion when saline and atropine are not adequate, and noradrenaline infusion is reported in a Nepali case series (Thapa et al. 2024). Noradrenaline addresses both components of GTX haemodynamic compromise: its beta-1 receptor effect provides chronotropic support, and its alpha-1 vasoconstrictor effect counters peripheral vasodilation that atropine does not directly address.

Catecholamine support is a bridging measure while GTX clears. Titrate to maintain adequate haemodynamic parameters and wean as the patient improves.

Step 4: Temporary Transvenous Pacemaker

Temporary pacemaker insertion is reserved for complete (third-degree) AV block unresponsive to pharmacological management. When AV conduction has completely failed, a ventricular escape rhythm at 20 to 40 bpm provides inadequate cardiac output. A temporary pacemaker restores adequate output while GTX clears.

The temporary designation is pharmacologically justified: GTX produces a reversible pharmacological blockade, not structural myocardial damage. As GTX is metabolised and eliminated, typically within 24 hours (Ullah et al. 2018), AV conduction resumes spontaneously. The pacemaker is removed once the patient demonstrates an adequate spontaneous rhythm. A permanent pacemaker is not indicated for GTX poisoning.

ECG Monitoring: Findings and Actions

Special Populations

Elderly patients have reduced cardiovascular reserve and age-related conduction slowing as baseline. GTX-induced impairment is superimposed, producing more severe presentations at comparable exposures. Anticholinergic atropine side effects are more pronounced; monitor for confusion and urinary retention.

Beta-blocker users present with combined bradycardia from two independent mechanisms: GTX vagal amplification and beta-1 blockade. Atropine addresses the vagal component; the beta-blocker effect remains. In severe persistent cases, glucagon may be considered extrapolated from beta-blocker overdose management, though this specific combination in GTX poisoning is not formally studied.

Pre-existing cardiac conditions, sick sinus syndrome, existing AV block, and documented arrhythmia are high-risk. A low threshold for early atropine and early pacemaker preparation is appropriate.

What Not to Do

Discharge Criteria and Observation Period

Observation times in the case record vary with severity. Aygun et al. (2018) discharged most of their 25 patients after 2 to 6 hours of cardiac monitoring in the emergency department, and Gunduz et al. (2006) kept patients for a 6-hour observation period. Longer stays are also reported: a mean of 14.7 hours in 21 patients (Demir et al. 2011), 18 to 48 hours in 21 patients (Demircan et al. 2009) and a mean of 27.7 hours in 16 patients (Yaylaci et al. 2014). In the largest review, patients were generally discharged within 24 hours after recovery (Silici and Atayoglu 2015). Severe cases were monitored in a coronary intensive care unit; in one series, the patient who needed a temporary pacemaker was discharged on the third day (Gunduz et al. 2006).

Discharge: published series discharged patients once sinus rhythm and blood pressure had returned to normal (Gunduz et al. 2006; Yaylaci et al. 2015); in one series, the mean heart rate at discharge was 75 beats per minute (Yaylaci et al. 2014). No anti-arrhythmic prophylaxis is required; GTX is a reversible pharmacological effect.

Evidence Base and Limitations

The protocol derives from retrospective clinical case series rather than randomised controlled trials. No RCT has evaluated any component. The dose ranges and escalation hierarchy are supported by convergent findings across hundreds of cases in the Turkish and Nepalese records. The absence of RCT evidence does not undermine the protocol’s utility: GTX has a well-characterised mechanism, and the treatment choices follow logically from it.

Individual reports are collected in CMHI’s Mad Honey Poisoning Case Log: 73 people treated in 8 countries since 2010, each row linked to the health authority release or journal case report it comes from.

What We Don’t Know Yet

Optimal atropine dosing has not been established by a controlled trial. The 0.5 to 2 mg reported in documented cases (Ullah et al. 2018) reflects what was used, not what has been pharmacologically optimised. The role of catecholamines in GTX poisoning has not been formally evaluated; use is extrapolated from general emergency medicine principles. Optimal monitoring duration has not been established by evidence-based criteria.

Summary Protocol Reference

Diagnose based on history plus triad. ECG immediately. No laboratory testing required to initiate treatment.

Mild (sinus bradycardia, no block): IV saline plus monitoring. Moderate (AV block): IV saline plus atropine. Severe (complete AV block, haemodynamic compromise): IV saline, atropine, catecholamine support, prepare pacemaker.

Temporary pacemaker for a complete AV block unresponsive to atropine. Wean when spontaneous conduction resumes. Published series observed mild cases for 2 to 6 hours and others for 18 to 48 hours; severe cases were monitored in intensive care. Published series discharged patients once sinus rhythm and blood pressure had returned to normal.

 

Sources

• Aygun A, et al. (2018), Grayanotoxin levels in blood, urine and honey and their association with clinical status in patients with mad honey intoxication. Turkish Journal of Emergency Medicine 18(1):29-33.
• Demir H, Denizbasi A, Onur O (2011), Mad Honey Intoxication: A Case Series of 21 Patients. ISRN Toxicology 2011:526426.
• Demircan A, et al. (2009), Mad Honey Sex: Therapeutic Misadventures From an Ancient Biological Weapon. Annals of Emergency Medicine 54(6):824-829.
• EFSA CONTAM Panel (2023), Risks for human health related to the presence of grayanotoxins in certain honey. EFSA Journal 21(3):7866.
• Gunduz A, et al. (2006), Mad honey poisoning. The American Journal of Emergency Medicine 24(5):595-598.
• Jansen SA, et al. (2012), Grayanotoxin Poisoning: ‘Mad Honey Disease’ and Beyond. Cardiovascular Toxicology 12(3):208-215.
• Okuyan E, Uslu A, Levent MO (2010), Cardiac effects of “mad honey”: a case series. Clinical Toxicology 48(6):528-532.
• Silici S, Atayoglu AT (2015), Mad honey intoxication: A systematic review on the 1199 cases. Food and Chemical Toxicology 86:282-290.
• Sumerkan MC, et al. (2013), Epidemiological evaluation of mad-honey intoxication (conference abstract OP-081). International Journal of Cardiology 163(3):S32-S33.
• Thapa AJ, et al. (2024), Mad honey (wild honey) poisoning: clinical case series from Nepal. Annals of Medicine & Surgery 86(9):4975-4978.
• Ullah S, et al. (2018), Mad honey: uses, intoxicating/poisoning effects, diagnosis, and treatment. RSC Advances 8(33):18635-18646.
• Yaylaci S, et al. (2014), Clinical and laboratory findings in mad honey poisoning: A single center experience. Nigerian Journal of Clinical Practice 17(5):589.
• Yaylacı S, et al. (2015), Is there a difference in mad honey poisoning between geriatric and non-geriatric patient groups?. European Review for Medical and Pharmacological Sciences 19(23):4647-4653.